Protiva Biotherapeutics Company Profile

21:50 EDT 24th March 2018 | BioPortfolio

Drug development using non-viral lipid-mediated gene delivery.


150 - 8900 Glenlyon Parkway
British Columbia
V5J 5J8

News Articles [182 Associated News Articles listed on BioPortfolio]

#jobs #lifescience MS Applications Chemist – Biotherapeutics

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MS Applications Chemist – Biotherapeutics .MA-Boston, MS Applications Chemi...

BRIEF—Hangzhou Just Biotherapeutics opens R&D center and GMP manufacturing facility

China-based Hangzhou Just Biotherapeutics (HJB), an organization dedicated to expanding global access…

ATUM, Just Biotherapeutics collaborate to speed up drug discovery

ATUM has signed a patent licensing agreement, which gives Just Biotherapeutics access to its Leap-In cell line development tools.

ATUM, Just Biotherapeutics collaborate to accelerate drug discovery

ATUM has entered into a patent licensing agreement with Just Biotherapeutics, providing access to the company’s Leap-In cell line development tools.

Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data

Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered v...

3 Best Biotherapeutics Stocks to Buy Right Now

Sometimes the biggest are also the best. That's the case for biotherapeutics stocks.

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy

BOSTON – December 18, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S....

Aeglea BioTherapeutics Updates Phase I/II Trial Data

Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]


Plasma Protein Fraction (Human) 5%, USPPlasmanate®


Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis.

Typically, quantitation of biotherapeutics from biological matrices by LC-MS is based on a surrogate peptide approach to determine molecule concentration. Recent efforts have focused on quantitation o...

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cell...

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?

Protein tyrosine phosphatases (PTPs), of the receptor and non-receptor classes, are key signaling molecules that play critical roles in cellular regulation underlying diverse physiological events. Abe...

Population-specific design of de-immunized protein biotherapeutics.

Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore...

Meeting report WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27-28 April 2017.

In April 2017, WHO convened an informal consultation to develop WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products. The objective of the meeting was to ...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [96 Associated Companies listed on BioPortfolio]

Protiva Biotherapeutics INC

Protiva is a development stage biotechnology company, focused on pharmaceutical products to fight serious human disease. Protiva's proprietary SNALP technology enables the development of novel nucleic...

Protiva Biotherapeutics

Drug development using non-viral lipid-mediated gene delivery.

Aevum Life Science

Aevum Life Science ™ was founded in 2010, to develop the highest quality, clinically focused products, to help women during pregnancy and while recovering and breast...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "Protiva Biotherapeutics" on BioPortfolio

We have published hundreds of Protiva Biotherapeutics news stories on BioPortfolio along with dozens of Protiva Biotherapeutics Clinical Trials and PubMed Articles about Protiva Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Protiva Biotherapeutics Companies in our database. You can also find out about relevant Protiva Biotherapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record